Skip to main content
Figure 2 | Cost Effectiveness and Resource Allocation

Figure 2

From: Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

Figure 2

Tornado diagram of the sensitivity analysis. Tornado diagram of the univariate sensitivity analysis showing the impact of individual cost parameters on the iCER per QALY. Parameter values of 75% and 125% of the base-case value were evaluated and these values are shown on both sides of the bars. All parameters refer to costs and are expressed in Euro price level 2006. TPV/r tipranavir with ritonavir. CPI/r comparator protease inhibitor with ritonavir. HAART highly active antiretroviral therapy. iCER incremental cost effectiveness ratio. QALY quality adjusted life year.

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us